Research from three countries adds support for the use of a booster dose of vaccines against SARS-CoV-2 in people with cancer, especially those undergoing active anticancer treatment.
Two papers from the prospective, longitudinal UK CAPTURE consortium shed light on the humoral and cellular immune response to SARS-CoV-2 vaccination and infection in patients with cancer.
An analysis of computed tomography scans from people with thoracic malignancies shows that approximately one in 11 people develop axillary lymphadenopathy following mRNA-based COVID-19 vaccination.